Clinicopathological features and prognostic factors of Japanese patients with "peripheral T-cell lymphoma, unspecified" diagnosed according to the WHO classification.
Clinicopathological features of 36 patients, male: 58.3%; median: 68 years, with "peripheral T-cell lymphoma, unspecified" diagnosed by the WHO criteria were reviewed. Majority (69.4%) had stage IV disease with frequent involvements into bone marrow, spleen, liver, and skin. According to the IPI, 72.2% were categorized as high or high-intermediate risk group. CR and PR were achieved in 12 and 10 out of 31 patients treated by CHOP-based chemotherapy, respectively. One- and two-year overall survivals were 60.6 and 25.0%, respectively. Performance status, serum LDH, and B symptom were significant prognostic factors. Survival of CD4-/CD8+ cases, corresponding to cytotoxic T-cell lymphoma, was significantly worse than that of CD4+/CD8-.
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. hkojima@md.tsukuba.ac.jp
Hiroshi
H
Kojima
Yuichi
Y
Hasegawa
Kazumi
K
Suzukawa
Harumi Y
HY
Mukai
Shin
S
Kaneko
Toshitaka
T
Kobayashi
Masaharu
M
Kamoshita
Atsushi
A
Shinagawa
Takuya
T
Komeno
Tsunehiko
T
Komatsu
Shoichi
S
Mitsuhashi
Yasuhiro
Y
Kawachi
Yoriko
Y
Yamashita
Naoyoshi
N
Mori
Toshiro
T
Nagasawa
D000328:Adult; D000368:Aged; D016516:CD4-CD8 Ratio; D002965:Classification; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007564:Japan; D016411:Lymphoma, T-Cell, Peripheral / Q000145:classification* / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic; D016896:Treatment Outcome; D014944:World Health Organization